Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Predictive Methods for Characterizing Product Performance in Pediatric Patients, Case Study: Furosemide
This project follows after earlier CDER research projects in which in vitro furosemide dissolution and/or solubility data were collected in various dissolution media such as simulated gastric and intestinal fluids.
In two different studies with different approaches and dissolution testing apparatus, furosemide dissolution was higher in medium containing milk and baby formula than that in standard buffer medium.
This research project will allow collecting in vivo data when furosemide (the model drug) will be given with milk, baby formula and Ensure Plus™ to healthy adults.
The suitability of the in vitro methods using dissolution media containing milk, baby formula and Ensure Plus for predicting in vivo performance of furosemide (a poorly soluble and poorly permeable drug), classified as BCS (Biopharmaceutic Classification System) Class IV drug will be determined.
In two different studies with different approaches and dissolution testing apparatus, furosemide dissolution was higher in medium containing milk and baby formula than that in standard buffer medium.
This research project will allow collecting in vivo data when furosemide (the model drug) will be given with milk, baby formula and Ensure Plus™ to healthy adults.
The suitability of the in vitro methods using dissolution media containing milk, baby formula and Ensure Plus for predicting in vivo performance of furosemide (a poorly soluble and poorly permeable drug), classified as BCS (Biopharmaceutic Classification System) Class IV drug will be determined.
Agency: Department of Health and Human Services
Office: Food & Drug Administration
Estimated Funding: $250,000
Office: Food & Drug Administration
Estimated Funding: $250,000
Obtain Full Opportunity Text:
NIH Guide for Grants and Contracts
Additional Information of Eligibility:
Not Available
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-13-035.html
Contact:
Oluyemisi (Yemisi) AkinneyeGrants Management SpecialistPhone 3018270079
Agency Email Description:
Oluyemisi.Akinneye@fda.hhs.gov
Agency Email:
Oluyemisi.Akinneye@fda.hhs.gov
Date Posted:
2013-07-19
Application Due Date:
2013-08-15
Archive Date:
2013-09-14
Social Entrepreneurship
Spotlight
When it Comes to Social Enterprises, Failure is the Best Platform for Innovation
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.
Learn How to Identify and Avoid Grant Scams
